½ÃÀ庸°í¼­
»óǰÄÚµå
1589465

¼¼°èÀÇ ´ç´¢º´ ¸Á¸·Áõ ½ÃÀå : À¯Çüº°, °ü¸®º° ¿¹Ãø(2025-2030³â)

Diabetic Retinopathy Market by Type (Non-proliferative DR, Proliferative DR), Management (Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery) - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 192 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

´ç´¢º´ ¸Á¸·Áõ ½ÃÀåÀº 2023³â 3¾ï 7,638¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 4¾ï 4,148¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 17.69%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 11¾ï 7,720¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´ç´¢º´ ¸Á¸·Áõ(DR)Àº ¸Á¸· Ç÷°ü¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ½Ã·Â Àå¾Ö¿Í ½Ç¸íÀ¸·Î À̾îÁö´Â ´ç´¢º´ À¯¹ß¼º ¾È ÁúȯÀÔ´Ï´Ù. ÀÌ ½ÃÀåÀÇ ºÐ¼® ¹üÀ§¿¡´Â DR °ü¸® ¶Ç´Â Ä¡·á¸¦ ¸ñÀûÀ¸·Î ÇÏ´Â ÇöÀçÀÇ Áø´Ü ±â¼ú, ÀǾàǰ Ä¡·á, ·¹ÀÌÀú Ä¡·á, ¿¹¹æ Ä¡·á¹ýÀÌ Æ÷ÇԵ˴ϴÙ. È¿À²ÀûÀÎ DR °ü¸®ÀÇ Çʿ伺Àº ¼¼°è ´ç´¢º´ Àα¸ Áõ°¡¿Í ´ç´¢º´ °ü·Ã ÇÕº´ÁõÀÇ ¹ß»ý·ü Áõ°¡·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. Á¶±â ¹ß°ß°ú Á¶±â °ü¸®´Â ½É°¢ÇÑ ½Ã·Â ÀúÇϸ¦ ¿¹¹æÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÏ¸ç ¾È°ú Ŭ¸®´Ð, º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ¾È°ú Àü¹® º´µ¿ µî ÀÀ¿ë ºÐ¾ßÀÇ ¼±ÅÃÀÌ Ç³ºÎÇÑ ºÐ¾ßÀÔ´Ï´Ù. ÁÖ¿ä ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î´Â ÀÇ·á¿ë È­»óó¸® ±â¼úÀÇ Áøº¸, ÀÇ½Ä Çâ»ó¿¡ÀÇ ´ëó, ´ç´¢º´°ú ´«ÀÇ °Ç°­¿¡ÀÇ ´ëó¿¡ ´ëÇÑ Á¤ºÎÀÇ ÀÚ±Ý ¿øÁ¶ µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. ÁÖ¸ñÇÒ¸¸ÇÑ °ÍÀº AI ÁÖµµ Áø´Ü µµ±¸¿Í ¿ø°Ý ÀÇ·á ¼Ö·ç¼Ç °³¹ßÀÌ ÃֽŠÀáÀç ±âȸ¸¦ Á¦½ÃÇÑ´Ù´Â °ÍÀÔ´Ï´Ù. ±â¾÷Àº ½º¸¶Æ®Æù¿ë ¾ÈÀú Ä«¸Þ¶ó³ª ¿þ¾î·¯ºí ¸ð´ÏÅ͸µ µð¹ÙÀ̽º µîÀÇ Çõ½ÅÀûÀÎ ±â¼ú¿¡ ÅõÀÚÇÔÀ¸·Î½á ÀÌÀÍÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª Áøº¸µÈ Áø´Ü ÀåºñÀÇ °í°¡ÀÇ ºñ¿ë, ¼÷·ÃµÈ ÀÇ·á Àü¹®°¡ ºÎÁ·, ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ Á¢±ÙÀÌ Á¦ÇÑµÈ Áö¿ª¿¡ ´ëÇÑ º¸±Þ °úÁ¦ µîÀ¸·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀº ÇѰ迡 Á÷¸éÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ±ÔÁ¦ ¹®Á¦¿Í Ä¡·á ¿É¼ÇÀÇ ÀáÀçÀû ºÎÀÛ¿ëÀÌ ½ÃÀå È®´ë¸¦ ¹æÇØÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °úÁ¦¿¡µµ ºÒ±¸Çϰí, ³·Àº ħ½À Ä¡·á ¿É¼ÇÀÇ Çõ½Å°ú °³º° ȯÀÚ¿¡°Ô ƯÀ¯ÀÇ DR ÁøÇàÀ» ¸ñÇ¥·Î ÇÑ ¸ÂÃãÇü ÀÇ·á Á¢±Ù¹ý¿¡´Â ±âȸ°¡ ÀÖ½À´Ï´Ù.°æÀïÀÌ Ä¡¿­ÇÑ ½ÃÀåÀ̱⠶§¹®¿¡ ¾à¹° Á¦Á¦ ¹× Áø´Ü ±â¼ú¿¡ Áö¼ÓÀûÀÎ Çõ½ÅÀÌ ¿ä±¸µÇ°í ºñ¿ë È¿À²¼º°ú Á¢±Ù¼ºÀÌ Áß¿äÇØÁý´Ï´Ù. ¼ú À» ÃËÁøÇÏ°í ±â¾÷À» ºñÀü ÄÉ¾î ½ÃÀåÀÇ ÃÖÀü¼±¿¡ À§Ä¡½Ãų ¼ö ÀÖ½À´Ï´Ù. ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ(2023) 3¾ï 7,638¸¸ ´Þ·¯
¿¹Ãø³â(2024) 4¾ï 4,148¸¸ ´Þ·¯
¿¹Ãø³â(2030) 11¾ï 7,720¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 17.69%

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ´ç´¢º´ ¸Á¸·Áõ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

´ç´¢º´ ¸Á¸·Áõ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ð¸¦ ÀÌ·ç°í ÀÖ½À´Ï´Ù. »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ ȹµæÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼¼°èÀÇ ´ç´¢º´ À¯º´·üÀÇ »ó½Â
    • ´ç´¢º´ÀÇ °ü¸®¿Í Äɾ °üÇÑ ÀǽÄÀÇ °íÁ¶
    • ´ç´¢º´ °ü¸®¸¦ ÃËÁøÇÏ´Â Á¤ºÎÀÇ ´ëó
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¼÷·ÃµÈ ¾È°ú ÀÇ»çÀÇ ºÎÁ·
  • ½ÃÀå ±âȸ
    • ÷´Ü Ä¡·á¹ý°ú ¾à¹°ÀÇ Áö¼ÓÀûÀÎ ¼Ò°³
    • ´ç´¢º´ Ȳ¹ÝºÎÁ¾ Ä¡·á¸¦ À§ÇÑ º´¿ë ¿ä¹ýÀÇ ÃâÇö
  • ½ÃÀåÀÇ °úÁ¦
    • ´ç´¢º´ ¸Á¸·Áõ Ä¡·áÁ¦ÀÇ ½ÂÀο¡ ½Ã°£ÀÌ °É¸± °Í

Porter's Five Forces : ´ç´¢º´ ¸Á¸·Áõ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀïÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» ¼³¸íÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¼öÀÖ´Â ´õ °­ÀÎÇÑ ½ÃÀå¿¡¼­ Æ÷Áö¼Å´×À» º¸Àå ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ´ç´¢º´ ¸Á¸·Áõ ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ´ç´¢º´ ¸Á¸·Áõ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ°¡ °¡´ÉÇÕ´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ´ç´¢º´ ¸Á¸·Áõ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

´ç´¢º´ ¸Á¸·Áõ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ´ÜÆíÈ­, ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í º¥´õµéÀº °æÀïÀÌ Ä¡¿­ÇØÁö´Â °¡¿îµ¥ ÀÚ»çÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ´ç´¢º´ ¸Á¸·Áõ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ´ç´¢º´ ¸Á¸·Áõ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ºÎ¹®È­Çϰí Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå ´ç´¢º´ ¸Á¸·Áõ ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ °æ·Î¸¦ ±×¸³´Ï´Ù.

´ç´¢º´ ¸Á¸·Áõ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ Á¸À縦 °­È­ÇÏ·Á´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ±¸ÃàÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀåÀÇ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡ÇÏ¸ç ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾ò°í ÀÇ»ç°áÁ¤À» ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹® ¹× Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ¼¼°èÀûÀ¸·Î ´ç´¢º´ÀÇ ÀÌȯÀ²ÀÌ »ó½Â
      • ´ç´¢º´ °ü¸® ¹× Äɾ °üÇÑ ÀǽÄÀÇ Çâ»ó
      • ´ç´¢º´ °ü¸®¸¦ ÃËÁøÇÏ´Â Á¤ºÎÀÇ ´ëó
    • ¾ïÁ¦¿äÀÎ
      • ¼÷·ÃµÈ ¾È°ú ÀÇ»çÀÇ ºÎÁ·
    • ±âȸ
      • ÷´Ü ´ç´¢º´ ¸Á¸·Áõ Ä¡·á¹ý°ú ¾à¹°ÀÇ Áö¼ÓÀûÀÎ ¼Ò°³
      • ´ç´¢º´ Ȳ¹Ý ºÎÁ¾ÀÇ Ä¡·á¿¡¼­ º¹ÇÕ ¿ä¹ýÀÇ ÃâÇö
    • °úÁ¦
      • ´ç´¢º´ ¸Á¸·Áõ ÀǾàǰÀÇ ½ÂÀÎ °úÁ¤¿¡ ½Ã°£ÀÌ °É¸°´Ù
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡Àû
    • °æÁ¦
    • »ç±³
    • ±â¼úÀû
    • ¹ý·ü»ó
    • ȯ°æ

Á¦6Àå ´ç´¢º´ ¸Á¸·Áõ ½ÃÀå : À¯Çüº°

  • ºñÁõ½Ä¼º DR
  • Áõ½Ä¼º DR

Á¦7Àå ´ç´¢º´ ¸Á¸·Áõ ½ÃÀå °æ¿µÁøº°

  • Ç× VEGF ¿ä¹ý
  • ¾È³» ½ºÅ×·ÎÀ̵å ÁÖ»ç
  • ·¹ÀÌÀú ¼ö¼ú
  • À¯¸®Ã¼ ÀýÁ¦¼ú

Á¦8Àå ¾Æ¸Þ¸®Ä«ÀÇ ´ç´¢º´ ¸Á¸·Áõ ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦9Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ´ç´¢º´ ¸Á¸·Áõ ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦10Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ´ç´¢º´ ¸Á¸·Áõ ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦11Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸ñ·Ï

  • Alimera Sciences, Inc.
  • Allergan PLC
  • Ampio Pharmaceuticals, Inc.
  • Bausch & Lomb Incorporated
  • Bayer AG
  • BCN PEPTIDES, SAU
  • F. Hoffmann-La Roche AG
  • Kodiak Sciences Inc.
  • Kowa Company, Ltd.
  • Novartis AG
  • Opthea Limited
  • Oxurion NV
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sirnaomics Inc.
BJH 24.11.21

The Diabetic Retinopathy Market was valued at USD 376.38 million in 2023, expected to reach USD 441.48 million in 2024, and is projected to grow at a CAGR of 17.69%, to USD 1,177.20 million by 2030.

Diabetic Retinopathy (DR) is a diabetes-induced eye condition that affects the retinal blood vessels and can lead to vision impairment and blindness. The scope of analysis within this market includes current diagnostic technologies, pharmaceutical treatments, laser therapies, and preventive care methods aimed at managing or treating DR. The necessity for efficient DR management arises from the growing global diabetic population and the increasing incidence of diabetes-related complications. Early detection and management are critical in preventing severe vision loss, making this an area rich with application options across eye care clinics, hospitals, outpatient surgical centers, and specialized ophthalmology wards. Key market growth drivers include advancements in medical imaging technologies, heightened awareness initiatives, and government funding for diabetes and eye health initiatives. Notably, the development of AI-driven diagnostic tools and telemedicine solutions presents the latest potential opportunities. Companies can benefit by investing in innovative technologies such as smartphone fundus cameras and wearable monitoring devices. However, market growth faces limitations driven by high costs of advanced diagnostic devices, lack of skilled healthcare professionals, and challenges in reaching rural areas with limited access to healthcare services. Furthermore, the market's expansion is hindered by regulatory challenges and potential side effects of treatment options. Despite these challenges, there are opportunities in the innovation of minimally invasive treatment options and personalized medicine approaches, targeting the unique progression of DR in individual patients. The market's competitive nature demands continuous innovation in drug formulations and diagnostic techniques, emphasizing cost-efficiency and accessibility. Fostering partnerships with technology firms and research institutions can generate significant insights and foster breakthroughs, thus positioning companies at the forefront of the vision care market. Overall, balancing technological advancements with affordability and accessibility will be crucial in capturing emerging markets and addressing the substantial unmet needs in diabetic retinopathy care.

KEY MARKET STATISTICS
Base Year [2023] USD 376.38 million
Estimated Year [2024] USD 441.48 million
Forecast Year [2030] USD 1,177.20 million
CAGR (%) 17.69%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Diabetic Retinopathy Market

The Diabetic Retinopathy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of diabetes globally
    • Increasing awareness associated with diabetic management and care
    • Government initiatives to promote the diabetes management
  • Market Restraints
    • Dearth of skilled ophthalmologists
  • Market Opportunities
    • Ongoing introduction of advanced diabetic retinopathy treatments and drugs
    • Emergence of combine therapies for treatment of diabetic macular edema
  • Market Challenges
    • Time consuming approval process for diabetic retinopathy drugs

Porter's Five Forces: A Strategic Tool for Navigating the Diabetic Retinopathy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Diabetic Retinopathy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Diabetic Retinopathy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Diabetic Retinopathy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Diabetic Retinopathy Market

A detailed market share analysis in the Diabetic Retinopathy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Diabetic Retinopathy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Diabetic Retinopathy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Diabetic Retinopathy Market

A strategic analysis of the Diabetic Retinopathy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Diabetic Retinopathy Market, highlighting leading vendors and their innovative profiles. These include Alimera Sciences, Inc., Allergan PLC, Ampio Pharmaceuticals, Inc., Bausch & Lomb Incorporated, Bayer AG, BCN PEPTIDES, S.A.U., F. Hoffmann-La Roche AG, Kodiak Sciences Inc., Kowa Company, Ltd., Novartis AG, Opthea Limited, Oxurion NV, Pfizer Inc., Regeneron Pharmaceuticals Inc., and Sirnaomics Inc..

Market Segmentation & Coverage

This research report categorizes the Diabetic Retinopathy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Non-proliferative DR and Proliferative DR.
  • Based on Management, market is studied across Anti-VEGF Therapy, Intraocular Steroid Injection, Laser Surgery, and Vitrectomy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of diabetes globally
      • 5.1.1.2. Increasing awareness associated with diabetic management and care
      • 5.1.1.3. Government initiatives to promote the diabetes management
    • 5.1.2. Restraints
      • 5.1.2.1. Dearth of skilled ophthalmologists
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing introduction of advanced diabetic retinopathy treatments and drugs
      • 5.1.3.2. Emergence of combine therapies for treatment of diabetic macular edema
    • 5.1.4. Challenges
      • 5.1.4.1. Time consuming approval process for diabetic retinopathy drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Diabetic Retinopathy Market, by Type

  • 6.1. Introduction
  • 6.2. Non-proliferative DR
  • 6.3. Proliferative DR

7. Diabetic Retinopathy Market, by Management

  • 7.1. Introduction
  • 7.2. Anti-VEGF Therapy
  • 7.3. Intraocular Steroid Injection
  • 7.4. Laser Surgery
  • 7.5. Vitrectomy

8. Americas Diabetic Retinopathy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Diabetic Retinopathy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Diabetic Retinopathy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Alimera Sciences, Inc.
  • 2. Allergan PLC
  • 3. Ampio Pharmaceuticals, Inc.
  • 4. Bausch & Lomb Incorporated
  • 5. Bayer AG
  • 6. BCN PEPTIDES, S.A.U.
  • 7. F. Hoffmann-La Roche AG
  • 8. Kodiak Sciences Inc.
  • 9. Kowa Company, Ltd.
  • 10. Novartis AG
  • 11. Opthea Limited
  • 12. Oxurion NV
  • 13. Pfizer Inc.
  • 14. Regeneron Pharmaceuticals Inc.
  • 15. Sirnaomics Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦